Study of a new treatment for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment approach for liver cancer that has spread or can't be removed. It aims to see if the study drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or has spread to other parts of the body.
- You must not have had prior systemic treatment (like pills or IV therapy) for advanced liver cancer.
- You must not have previously taken certain targeted drugs (like sorafenib or lenvatinib) or immunotherapy (like PD-1 inhibitors).
- You must have at least one tumor that can be measured on scans.
- Your liver function must be good enough (Child-Pugh score 7 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed therapy given before surgery to shrink tumors in people with early-stage liver cancer that can be removed. The goal is to make surgery more successful and improve outcomes.
This study tests a new combination treatment for advanced liver cancer that has stopped responding to earlier therapy. It combines the targeted drug donafenib with immunotherapy and local treatments, which may help control the tumor better than the previous treatments.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
This study looks back at patients who received a combination of donafenib (a targeted pill), immunotherapy (a medicine that helps your immune system fight cancer), and a liver-directed procedure (TACE or HAIC) as their first treatment for liver cancer that can't be surgically removed. The goal is to check how well this combination works and how safe it is.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. The treatments include a targeted therapy pill, a procedure that cuts off blood supply to the tumor, and radiation, plus an immunotherapy drug that helps your immune system fight the cancer. This approach aims to shrink tumors and improve outcomes.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.